On Aug. 29, 2016, Seqirus announced that the U.S. Food and Drug Administration (FDA) had approved AFLURIA® QUADRIVALENT (Influenza Vaccine) for use in persons 18 years of age and older.

AFLURIA QUADRIVALENT is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. Both AFLURIA QUADRIVALENT and AFLURIA® (Influenza Vaccine), were available in the US for the 2016-2017 influenza season.

AFLURIA QUADRIVALENT is the second quadrivalent influenza vaccine that Seqirus was offering this season after the FDA approved FLUCELVAX QUADRIVALENT™ (Influenza Vaccine) in May. AFLURIA QUADRIVALENT comes in single-dose, preservative-free pre-filled syringes while AFLURIA, indicated for persons 5 years of age and older, is available in prefilled syringes and multi-dose vials to provide choice and convenience to patients and caregivers who administer it.